Study Highlights**WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?**☑ Reactive genotype testing is the most common model for pharmacogenetic implementation. **WHAT QUESTION DID THIS STUDY ADDRESS?**☑ Demonstrate the clinical utility of preemptive, panel‐based testing among patients with post‐percutaneous coronary intervention to guide pharmacogenetic drug prescribing beyond cytochrome P450 family 2 subfamily C member 19 (*CYP2C19*) testing. **WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?**☑ Data from two cohorts of patients who underwent percutaneous coronary intervention (PCI) within MarketScan and University of Florida Health Precision Medicine Program demonstrate a high prevalence of pharmacogenetic drugs and actionable genotypes among patients who undergo PCI. **HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE**☑ Pre‐emptive, panel‐based testing at the time of PCI could lead to genotype‐guided prescribing decisions in over a third of patients, improving drug therapy outcomes beyond *CYP2C19* testing for antiplatelet therapy selection.

 {#cts12729-sec-0002}

Pharmacogenetics offers the potential to improve patient outcomes and drug safety through genotype‐guided approaches.[1](#cts12729-bib-0001){ref-type="ref"} Implementation efforts span from testing for a single gene at the time of drug prescribing (i.e., reactive testing model) to testing for multiple genes as part of a pharmacogenetics panel ahead of the need for drug therapy (i.e., preemptive, multipharmacogene, and panel‐based testing model). Although the latter may offer efficiencies, only the former is currently reimbursed by third party payers.[2](#cts12729-bib-0002){ref-type="ref"}

A major barrier with a reactive testing model is the genotype turnaround time, which may affect clinical adoption of pharmacogenetics and widespread uptake in diverse health systems. Specifically, delays in turnaround time can lead to unavailability of genotype information at the time of prescribing. Clinicians would need to follow‐up with patients after genotype results are returned if results dictate a change in therapy. This can negatively impact work flow.[3](#cts12729-bib-0003){ref-type="ref"} Pre‐emptive pharmacogene panel‐based testing, on the other hand, may represent a more efficient model for pharmacogenetics implementation[4](#cts12729-bib-0004){ref-type="ref"} as it allows for the availability of genotype data at the time of prescribing for multiple medications.

Opponents of a preemptive approach argue that it may lead to unnecessary genotyping for drugs to which patients may never be exposed.[4](#cts12729-bib-0004){ref-type="ref"} Previous studies in general patient populations have reported a high prevalence of exposure to medications for which there is strong evidence for genetic associations with adverse events or clinical benefits.[5](#cts12729-bib-0005){ref-type="ref"}, [6](#cts12729-bib-0006){ref-type="ref"} However, no study has focused such estimates on a concrete example of patients who underwent percutaneous coronary intervention (PCI). PCI is one of the most common clinical scenarios in which pharmacogenetic testing occurs[7](#cts12729-bib-0007){ref-type="ref"}, [8](#cts12729-bib-0008){ref-type="ref"} and for which testing is covered by most insurance plans. Additionally, patients who undergo PCI are considered high‐risk patients who are characterized by polypharmacy.[9](#cts12729-bib-0009){ref-type="ref"} Thus, preemptive testing for gene‐drug pairs that are frequently prescribed to this patient population may be cost‐effective.

We aimed to estimate opportunities for genotype‐guided prescribing, beyond cytochrome P450 family 2 subfamily C member 19 (*CYP2C19*)‐guided antiplatelet prescribing, following pharmacogene panel‐based testing at the time of PCI. To accomplish this aim, a large claims database representative of commercially insured patients in the United States was utilized to identify prevalence of pharmacogenetic medications, with a focus on patients who underwent PCI. Information on pharmacogenetic variants and prescription of pharmacogenetic medications were assessed in a second cohort of patients who underwent PCI and clinical *CYP2C19* genotyping as part of the Precision Medicine Program at the University of Florida Health (UF). The design of the study is outlined in **Figure** [1](#cts12729-fig-0001){ref-type="fig"}.

![Study design outline. CPIC, Clinical Pharmacogenetic Implementation Consortium; *CYP2C9*, cytochrome P450 family 2 subfamily C member 9; *CYP2C19*, cytochrome P450 family 2 subfamily C member 19; *CYP2D6*, cytochrome P450 family 2 subfamily D member 6; PCI, percutaneous coronary intervention; *SLCO1B1*, solute carrier organic anion transporter family 1B1; UF, University of Florida; *VKORC1*, vitamin K epoxide reductase complex subunit 1.](CTS-13-473-g001){#cts12729-fig-0001}

Materials and methods {#cts12729-sec-0003}
=====================

IBM MarketScan cohort {#cts12729-sec-0004}
---------------------

Using IBM MarketScan Commercial claims data from 2008--2015, we created a cohort of patients who underwent PCI. Patients 18--64 years old were included in the analysis if they had at least 6 months of continuous enrollment in a health plan prior to the first identified PCI. We defined an index PCI as any inpatient or outpatient encounter claim for PCI identified through current procedural terminology codes or *International Classification of Diseases--Ninth Revision* procedure codes (**Table** [**S1**](#cts12729-sup-0001){ref-type="supplementary-material"}), in addition to a pharmacy dispensing claim for clopidogrel, prasugrel, or ticagrelor within 7 days of PCI. Although among antiplatelet therapies only clopidogrel is influenced by *CYP2C19*, the initiation of prasugrel or ticagrelor may have been a direct result of *CYP2C19* testing. Thus, initiators of any of the three antiplatelet agents were included. To identify the most frequently prescribed pharmacogenetic medications in addition to antiplatelet regimens among patients who underwent PCI, we estimated the prevalence of additional drugs with a high level of evidence supporting genotype‐guided prescribing, using pharmacy billing records. We defined such pharmacogenetic drugs (**Table** [**S2**](#cts12729-sup-0001){ref-type="supplementary-material"}) as having Clinical Pharmacogenetic Implementation Consortium (CPIC) level A/B evidence (Pharmacogenomics Knowledgebase evidence 1A through 2A, whose effects are modified by genotypes at *CYP2C19*, cytochrome P450 family 2 subfamily D member 6 (*CYP2D6*), cytochrome P450 family 2 subfamily C member 9 (*CYP2C9*), vitamin K epoxide reductase complex subunit 1 (*VKORC1*), or solute carrier organic anion transporter family member 1B1 (*SLCO1B1*)). We focused on these genes because they are most often captured on the pharmacogenetics panels.[10](#cts12729-bib-0010){ref-type="ref"}

The assessed drugs (CPIC level A/B) included those with current CPIC guidance or significant literature supporting genetic associations with response, some which are under CPIC consideration (e.g., proton pump inhibitors (PPIs)[11](#cts12729-bib-0011){ref-type="ref"} and celecoxib). Only drugs prescribed after initiation of any of the three antiplatelet agents were assessed.

First, we determined the prevalence of additional pharmacogenetic drugs among beneficiaries, without requiring a minimum length of health plan enrollment. These data are expected to inform payers about the prevalence of pharmacogenetic drugs among beneficiaries regardless of the length of coverage. Second, we created cohorts of varying periods of continuous plan enrollment (1 year through 5 years), in whom we determined annual or multi‐annual prevalence of CPIC level A and CPIC level A or B drug use. We specifically used the drug prevalence data over 1 year and 5 years for patients who survived throughout the follow‐up period and had at least 1 year (*N* = 105,547) and 5 years (*N* = 12,462) of follow‐up data, to project the short‐term and long‐term utility of preemptive genotyping, regardless of switches in health plans (**Figure** [1](#cts12729-fig-0001){ref-type="fig"}).

UF Health Personalized Medicine Program PCI cohort {#cts12729-sec-0005}
--------------------------------------------------

In 2012, the Precision Medicine Program at UF Health Shands Hospital initiated *CYP2C19* testing for patients at the time of left heart catheterization (LHC), anticipating that many of these patients would proceed to PCI and require a P2Y~12~ receptor inhibitor.[12](#cts12729-bib-0012){ref-type="ref"} Testing was expanded to UF Health in Jacksonville in 2016, which also focused on patients undergoing LHC with intent for PCI.[13](#cts12729-bib-0013){ref-type="ref"} For the purpose of this study, we included 211 patients (mean age 65 ± 11 years) who were genotyped for *CYP2C19*, underwent PCI, and consented to storage of their excess blood samples for DNA biobanking and future research[14](#cts12729-bib-0014){ref-type="ref"} (**Figure** [1](#cts12729-fig-0001){ref-type="fig"}).

Genotyping methods {#cts12729-sec-0006}
------------------

Genomic DNA from the 211 UF Health patients was isolated using FlexiGene DNA Kit (Qiagen, Valencia, CA) according to kit manufacturer instructions and genotyped using a fluorescence‐based TaqMan OpenArray QuantStudio RealTime PCR System[15](#cts12729-bib-0015){ref-type="ref"} (Applied Biosystems, Life Technologies, Boston, MA, USA) for common genetic variants in *CYP2C19*, *CYP2D6*, *SLCO1B1*, *CYP2C9*, and *VKORC1* (**Table** [1](#cts12729-tbl-0001){ref-type="table"}). Only single nucleotide polymorphisms (SNPs) and not copy number variation or gene deletion (*CYP2D6\*5*) were determined, precluding the evaluation of CYP2D6 ultra‐rapid metabolizer (UM), and reducing the prevalence of CYP2D6 intermediate metabolizer (IM) and poor metabolizer (PM) phenotype status. Genotyping accuracy for SNPs in *CYP2C19*, *CYP2C9*, *VKORC1*, and *SLCO1B1* was validated against the high resolution melting methodology, in which genotyping concordance was documented to range between 99.1% and 100%.[15](#cts12729-bib-0015){ref-type="ref"} To ascertain the validity of *CYP2D6* genotyping, 60 samples were randomly selected for pyrosequencing (PSQ HS 96; Qiagen) for *\*4*, *\*10*, *\*17*, and *\*41* variants,[16](#cts12729-bib-0016){ref-type="ref"} for which 100% genotype concordance was observed. All samples (*n* = 211) were successfully genotyped for SNPs of interest in the five genes.

###### 

SNPs genotyped in patients who underwent percutaneous coronary intervention at UF Health and consented to DNA biobanking

  Gene                                  SNPs
  ------------------------------------- -----------------------------------------------------
  *CYP2C19*                             *\*2* (c.681G\>A, rs4244285)
  *\*3* (c.636G\>A, rs4986893)          
  *\*4* (c.1A\>G, rs28399504)           
  *\*6* (c.395G\>A, rs72552267)         
  *\*8* (c.358T\>C, rs41291556)         
  *\*17* (c.‐806C\>T, rs12248560)       
  *SLCO1B1*                             *\*5* (c.521T\>C, rs4149056)
  *CYP2C9*                              *\*2* (c.430C\>T, rs1799853)
  *\*3* (c.1075A\>C, rs1057910)         
  *\*5* (c.1080C\>G, rs28371686)        
  *\*8* (c.449G\>A, rs7900194)          
  *\*11* (c.1003C\>T, rs28371685)       
  *\*14* (c.374G\>A, rs72558189*)*      
  *VKORC1*                              ‐1639G\>A (rs992323)
  *CYP2D6*                              *\*2* (c.886C\>T, rs16947); (c.1457G\>C, rs1135840)
  *\*3* (c.775delA, rs35742686)         
  *\*4* (c.506‐1G\>A, rs3892097)        
  *\*6* (c.363‐141delT, rs5030655)      
  *\*10* (c.100C\>T, rs1065852)         
  *\*17* (c.320C\>T, rs28371706)        
  *\*41* (c.841 + 39G\>A, rs28371725)   

*CYP2C9*, cytochrome P450 family 2 subfamily C member 9; *CYP2C19*, cytochrome P450 family 2 subfamily C member 19; *CYP2D6*, cytochrome P450 family 2 subfamily D member 6; *SLCO1B1*, solute carrier organic anion transporter family member 1B1; SNPs, single nucleotide polymorphisms; UF, University of Florida; *VKORC1*, vitamin K epoxide reductase complex subunit 1.
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The study component related to the UF Health Precision Medicine Program was approved by the UF Institutional Review Board, whereas the MarketScan‐related analysis was deemed exempt by the UF Institutional Review Board because of the use of de‐identified data.

Definition of actionable genotypes/phenotypes {#cts12729-sec-0007}
---------------------------------------------

The star diplotype nomenclature was assigned for the assessed *CYP450* gene using the translation tables from the PharmGKB website.[17](#cts12729-bib-0017){ref-type="ref"} We evaluated whether a genotype was actionable based on an understanding of its effect on drug response phenotype, consistent with the approach adopted by CPIC.[18](#cts12729-bib-0018){ref-type="ref"} A gene‐drug pair was considered "actionable" if the genotype would influence selection of a drug or drug dose, and, thus, was assigned specific recommendations/guidance from CPIC. For drugs with CPIC level B evidence, for which CPIC guidelines are in process (e.g., PPIs and celecoxib, personal communication from CPIC), we defined actionable genotypes according to available literature and/or other professional guidelines such as those put forward by the Dutch Pharmacogenetics Working Group.[19](#cts12729-bib-0019){ref-type="ref"}, [20](#cts12729-bib-0020){ref-type="ref"} A similar approach was taken for drugs meeting evidence‐level criteria for inclusion but with no current CPIC guidelines (risperidone and venlafaxine).

The term "actionable phenotype" was dependent on the evaluated gene‐drug pair. For example, *CYP2C19* UM, rapid metabolizer, and PM phenotypes were considered "actionable" for tricyclic antidepressants (amitriptyline, clomipramine, imipramine, and doxepin), PPIs, and certain selective serotonin reuptake inhibitors (citalopram and escitalopram).[21](#cts12729-bib-0021){ref-type="ref"} However, only the *CYP2C19* PM phenotype was considered "actionable" for sertraline per CPIC guidance.[21](#cts12729-bib-0021){ref-type="ref"}, [22](#cts12729-bib-0022){ref-type="ref"} For warfarin, we evaluated the combination of both *CYP2C9* diplotypes and *VKORC1‐1639* c.G\>A (rs992323) to determine warfarin sensitivity phenotypes.[23](#cts12729-bib-0023){ref-type="ref"} For example, a highly sensitive warfarin was defined as a combination of *VKORC1* rs9923231 AA plus *CYP2C9* \*1/\*3, \*2/\*2, \*2/\*3, or \*3/\*3; *VKORC1* rs9923231 GG plus CYP2C9 \*3/\*3, or *VKORC1* rs9923231 AG plus *CYP2C9* \*3/\*3 or \*2/\*3. A sensitive warfarin was defined as *VKORC1* rs9923231 GG plus *CYP2C9* \*1/\*3; *VKORC1* rs9923231 AG plus a *CYP2C9* heterozygote genotype (e.g., \*1/\*3 and \*1/\*2), or homozygote *CYP2C9* variant genotype (\*2/\*2), or compound *CYP2C9* heterozygote (\*2/\*3).

We assessed opioids that met the criterion for inclusion (CPIC level A) or are not considered good alternatives for patients with CYP2D6 IM/PM phenotypes (codeine, oxycodone, and tramadol).[24](#cts12729-bib-0024){ref-type="ref"} Although CYP2D6 UM phenotype status is considered "actionable" for some drugs, such as opioids and ondansetron, it was not assessed in our study because we did not quantify copy number variants.

For each patient, the number of actionable phenotypes was determined based on their diplotypes at *CYP2C19*, *CYP2D6*, *CYP2C9*, *SLCO1B1*, and combination of *CYP2C9* and *VKORC1* (warfarin sensitivity). For example, if a patient had a *CYP2C19\*17/\*17*, *CYP2D6\*1/\*1*, *VKORC1 ‐*1639AA, *CYP2C9\*2/\*3*, and *SLCO1B1\*5*, then this patient would be considered actionable for four phenotypes (CYP2C19 UM, CYP2C9 PM, warfarin high sensitivity, and risk of muscle toxicity).

Projection of genotype‐guided drug prescribing decisions following PCI using 1 year and 5 year drug prevalence data (MarketScan) and prevalence of actionable phenotypes (UF) {#cts12729-sec-0008}
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Following PCI and antiplatelet initiation, we estimated the 1‐year and 5‐year genotype‐guided prescribing opportunities (excluding the initial decision regarding *CYP2C19*‐guided antiplatelet therapy). The projected genotype‐guided prescribing opportunities were calculated by considering the 5 evaluated genes in the UF PCI cohort (**Table** [1](#cts12729-tbl-0001){ref-type="table"}) and 30 pharmacogenetic drugs (**Table** [**S3**](#cts12729-sup-0001){ref-type="supplementary-material"}). Additionally, gene‐drug pairs that are influenced by CYP2D6 UM were not included. The prevalence of each actionable phenotype (derived from UF data) was multiplied by the 1‐year and 5‐year post‐PCI prevalence data of the corresponding medication (determined from MarketScan) to calculate the projected 1 year and 5 year\'s genotype‐guided prescribing opportunity, respectively.

To contrast drug utilization data from our national sample (MarketScan) with our UF population (which provided the phenotype prevalence), we extracted 1‐year post‐PCI inpatient and outpatient prescriptions from UF electronic health records. As a validation for our projections in MarketScan, we defined the actual genotype‐guided prescribing opportunities in UF as the percentage of patients with actionable phenotypes who were prescribed the relevant pharmacogenetic drug(s).

Results {#cts12729-sec-0009}
=======

Prevalence of actionable phenotypes in UF patients who underwent PCI {#cts12729-sec-0010}
--------------------------------------------------------------------

The average age of the UF patient cohort (*N* = 211) was 65 ± 11 years; 46% were white, 48% were African American, 1% were Asians, and 5% were multiracial or of unknown race. The genotype/phenotype prevalence is summarized in **Table** [2](#cts12729-tbl-0002){ref-type="table"}. Seventy‐seven percent of UF patients had at least one actionable phenotype for the evaluated genes; 56% for *CYP2C19*, 5% for *CYP2D6*, 25% for *CYP2C9*, 22% for the combination of *VKORC1/CYP2C9* (warfarin sensitivity), and 15% for *SLCO1B1.*

###### 

Prevalence of actionable phenotypes for five genes among patients with PCI at the UF (*N* = 211)

  Gene                                                              Phenotypes                                                                 Example genotypes                                                    Prevalence of actionable phenotypes (%)
  ----------------------------------------------------------------- -------------------------------------------------------------------------- -------------------------------------------------------------------- -----------------------------------------
  *CYP2C19*                                                         RM/UM                                                                      *\*1/\*17*; *\*17/\*17*                                              33.2
  IM                                                                *\*1/\*2*; *\*1/\*3*; *\*1/\*8*                                            19.9                                                                 
  PM                                                                *\*2/\*2*; *2/\*3*                                                         2.4                                                                  
  Provisional IM[a](#cts12729-note-0005){ref-type="fn"}             *\*2/\*17*                                                                 7.6                                                                  
  *CYP2D6*                                                          IM                                                                         *\*4/\*41*; *\*4/10*; *\*4/\*17*                                     3.3
  PM                                                                *\*4/\*6*; *\*4/\*4*; *\*3/\*4*                                            1.9                                                                  
  *CYP2C9*                                                          IM                                                                         *\*1/\*2*; *\*1/\*3*; *\*1/\*5*; *\*1/\*8*;*\*1/\*11*                23.2
  PM                                                                *\*2/\*2*; *\*2/\*3*; *3/\*3*                                              1.4                                                                  
  *VKORC1 + CYP2C9*                                                 Highly warfarin sensitive[b](#cts12729-note-0005){ref-type="fn"}           *VKORC1* AG + *CYP2C9* *\*2/\*3*; *VKORC1* AA + *CYP2C9* *\*1/\*3*   1.42
  Warfarin sensitive[c](#cts12729-note-0005){ref-type="fn"}         *VKORC1* GG + *CYP2C9* *\*2/\*3*; *VKORC1* AG + *CYP2C9* *\*1/\*2*         20.4                                                                 
  *SLCO1B1*                                                         Intermediate transporter function[d](#cts12729-note-0005){ref-type="fn"}   rs4149056 CT                                                         12.8
  Low transporter function[d](#cts12729-note-0005){ref-type="fn"}   rs4149056 CC                                                               1.9                                                                  

*CYP2C9*, cytochrome P450 family 2 subfamily C member 9; *CYP2C19*, cytochrome P450 family 2 subfamily C member 19; *CYP2D6*, cytochrome P450 family 2 subfamily D member 6; IM, intermediate metabolizer; PCI, percutaneous coronary intervention; PM, poor metabolizer; RM, rapid metabolizer; *SLCO1B1*, solute carrier organic anion transporter family member 1B1; UF, University of Florida; UM, ultra‐rapid metabolizer; *VKORC1*, vitamin K epoxide reductase complex subunit 1.

^a^The actionable phenotype for *CYP2C19 \*2/\*17* is a provisional classification. ^b^ Highly warfarin sensitive: *VKORC1* rs9923231 AA plus *CYP2C9 \*1/\*3*, *\*2/\*2*, *\*2/\*3*, or *\*3/\*3*; *VKORC1* rs9923231 GG plus *CYP2C9* \**3/\*3*, *VKORC1* rs9923231 AG plus *CYP2C9 \*3/\*3* or *\*2/\*3.* ^c^Sensitive warfarin: *VKORC1* rs9923231 GG plus *CYP2C9 \*1/\*3*; *VKORC1* rs9923231 AG plus a *CYP2C9* heterozygote genotype (e.g., *\*1/\*3* and *\*1/\*2*), homozygote *CYP2C9* variant genotype (\*2/\*2), or compound *CYP2C9* heterozygote (\*2/\*3). ^d^Both intermediate and low transporter function are risk phenotypes for muscle toxicities.
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Prevalence of medications with pharmacogenetic guidance in MarketScan {#cts12729-sec-0011}
---------------------------------------------------------------------

Within the MarketScan database, 155,006 patients had a PCI and were prescribed clopidogrel, prasugrel, or ticagrelor, whereby no minimum continuous enrollment period after PCI was required. Patients had a total of 312,031 patient‐years of follow‐up during which 44,331 (28.6%) were prescribed at least 1 additional drug with CPIC level A evidence, and 62,157 (40.1%) were prescribed at least 1 additional drug with CPIC level A or B evidence. The prevalence of dispensed pharmacogenetic medications for patients with 1, 3, and 5 years of continuous enrollment is shown in **Table** [3](#cts12729-tbl-0003){ref-type="table"} and **Figure** [2](#cts12729-fig-0002){ref-type="fig"}. Among 105,547 patients who underwent PCI, who were initiated on antiplatelet therapy, and had at least 1‐year continuous enrollment data, 36.3% were prescribed at least 1 additional drug with CPIC level A evidence, and 50% were prescribed at least 1 additional drug with CPIC level A or B evidence over 1 year. For patients with at least 5 years of follow‐up data, more than one quarter of patients were prescribed three or more CPIC level A or B drugs (**Table** [3](#cts12729-tbl-0003){ref-type="table"}).

###### 

Prevalence of CPIC level A and B drugs prescribed after PCI and antiplatelet initiation among patients with at least 1, 3, and 5 years\' follow‐up data in MarketScan (2008--2015)

  Antiplatelet therapy initiators                       
  --------------------------------- ------------------- ---------------
  **1‐year follow‐up**              ***N* = 105,547**   
  0 prescriptions                   52,748 (50.0)       67,254 (63.7)
  1--2                              37,760 (35.8)       32,804 (31.1)
  3--4                              11,757 (11.1)       4,782 (4.5)
  5--6                              2,690 (2.5)         604 (0.6)
  \> 6                              592 (0.6)           103 (0.1)
  **3‐year follow‐up**              ***N* = 39,962**    
  0 prescriptions                   15,631 (39.1)       20,969 (52.5)
  1--2                              15,706 (39.3)       15,264 (38.2)
  3--4                              6,361 (16.0)        3,328 (8.3)
  5--6                              1,816 (4.5)         370 (0.9)
  \> 6                              448 (1.1)           31 (0.1)
  **5‐year follow‐up**              ***N* = 12,462**    
  0 prescriptions                   3,989 (32.0)        5,577 (44.8)
  1--2                              5,050 (40.5)        5,299 (42.5)
  3--4                              2,397 (19.2)        1,389 (11.1)
  5--6                              786 (6.3)           180 (1.4)
  \> 6                              240 (2.0)           17 (0.1)

CPIC, Clinical Pharmacogenetics Implementation Consortium; PCI, percutaneous coronary intervention.

Zero, 1--2, 3--4, 5--6, and \> 6 prescriptions refer to the number of prescriptions for drugs with pharmacogenetic evidence (CPIC level A or B or CPIC level A only) that were prescribed in addition to antiplatelet therapy for cohorts with at least 1 year, 3 years, and 5 years of continuous enrollment.
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![Proportion of patients prescribed at least one additional Clinical Pharmacogenetic Implementation Consortium (CPIC) drug over 1 year through 5 years following percutaneous coronary intervention.](CTS-13-473-g002){#cts12729-fig-0002}

As shown in **Table** [4](#cts12729-tbl-0004){ref-type="table"} **and** **Tables** [**S3**](#cts12729-sup-0001){ref-type="supplementary-material"} and [**S4**](#cts12729-sup-0001){ref-type="supplementary-material"}, opioids, PPIs,and simvastatin were the most commonly prescribed pharmacogenetic medications among patients within MarketScan at both 1 and 5 years.

###### 

Prevalence of prescribed pharmacogenetics drugs, projected and actual 1‐year genotype‐guided opportunities among post‐PCI patients in MarketScan (*n* = 105,547) and UF (*n* = 211)

  Gene                                  CPIC (Level A or B)   Actionable phenotype                        Phenotype prevalence (%) at UF   MarketScan   UF            
  ------------------------------------- --------------------- ------------------------------------------- -------------------------------- ------------ ------ ------ ------
  *CYP2D6*                              Oxycodone             PM, IM                                      5.2                              21.4         1.1    29.9   0.9
  Codeine                               18.5                  1.0                                         1.4                                                         
  Tramadol                              16.3                  0.8                                         13.7                                                        
  Methadone                             0.3                   0.02                                        0.0                                                         
  Nortriptyline                         PM, IM                5.2                                         0.9                              0.05         1.4    0.5    
  Desipramine                           0.1                   0.005                                       0.0                                                         
  Venlafaxine                           2.6                   0.1                                         1.4                                                         
  Risperidone                           0.3                   0.02                                        0.3                                                         
  Paroxetine                            PM                    1.9                                         2.5                              0.05         0.5    0.0    
  Fluvoxamine                           0.1                   0.002                                       0.0                                                         
  Mirtazapine                           0.9                   0.02                                        0.5                                                         
  *CYP2C19*                             Omeprazole            PM, IM RM, UM                               55.5                             19.6         10.9   8.5    22.7
  Pantoprazole                          16.0                  8.9                                         36.0                                                        
  Lansoprazole                          5.1                   2.8                                         0.5                                                         
  Rabeprazole                           0.8                   0.4                                         0.0                                                         
  *CYP2C19*                             Citalopram            PM, RM, UM                                  35.6                             6.2          2.2    2.4    1.4
  Escitalopram                          5.1                   1.8                                         2.4                                                         
  Voriconazole                          0.1                   0.04                                        0.0                                                         
  Sertraline                            PM                    2.4                                         4.6                              0.1          3.8    0.0    
  *SLCO1B1*                             Simvastatin           Low and intermediate transporter activity   14.7                             36.6         5.4    8.1    1.9
  *CYP2C19/CYP2D6*                      Amitriptyline         CYP2C19 PM RM/UM/ or CYP2D6 IM/PM           39.8                             2.6          1.0    2.8    1.9
  Doxepin                               0.6                   0.2                                         1.4                                                         
  Imipramine                            0.2                   0.08                                        0.0                                                         
  Clomipramine                          0.0                   0.0                                         0.0                                                         
  *VKORC1 + CYP2C9*                     Warfarin              Warfarin sensitive or highly sensitive      21.8                             6.0          1.3    8.1    2.4
  *CYP2C9*                              Phenytoin             IM, PM                                      24.6                             0.3          0.07   0.5    0.5
  Celecoxib                             PM                    1.4                                         2.7                              0.04         0.5           
  Total genotype‐guided opportunities   38.5%                 32.2%                                                                                                   

Total projected 1‐year genotype‐guided therapy decisions = (∑ prevalence of actionable phenotype in UF × prevalence of relevant drug over a year in MarketScan).

Actual genotype‐guided opportunity for each gene‐drug/drug‐class was defined as the percentage of patients with the actual phenotype and a prescription for the relevant pharmacogenetic drug. Drugs affected by the CYP2D6 UM phenotype (such as ondansetron) are not listed in the table because copy number variation was not assessed, and, therefore, projected and actual genotype‐guided prescribing decisions were not determined.

*CYP2C9*, cytochrome P450 family 2 subfamily C member 9; *CYP2C19*, cytochrome P450 family 2 subfamily C member 19; *CYP2D6*, cytochrome P450 family 2 subfamily D member 6; IM, intermediate metabolizer; PCI, percutaneous coronary intervention; PM, poor metabolizer; RM, rapid metabolizer; *SLCO1B1*, solute carrier organic anion transporter family member 1B1; UF, University of Florida; UM, ultra‐rapid metabolizer; *VKORC1*, vitamin K epoxide reductase complex subunit 1.

John Wiley & Sons, Ltd

Projecting genotype‐guided drug prescribing opportunities post‐PCI {#cts12729-sec-0012}
------------------------------------------------------------------

Among MarketScan antiplatelet initiators with at least 1 year of post‐PCI enrollment data (*n* = 105,547), the projected, 1‐year incidence of unique genotype‐guided drug prescribing (∑ prevalence of actionable phenotype in UF × prevalence of relevant drug in MarketScan) was 39% (**Table** [4](#cts12729-tbl-0004){ref-type="table"}). This was primarily the contribution of actionable *CYP2C19* and *SLCO1B1* phenotypes influencing PPIs and simvastatin prescribing decisions. The projected incidence of genotype‐guided prescribing decisions increased to 52% when the 5‐year prevalence data of pharmacogenetic drugs were used (**Table** [**S4**](#cts12729-sup-0001){ref-type="supplementary-material"}).

Potential genotype‐guided prescribing opportunities within UF {#cts12729-sec-0013}
-------------------------------------------------------------

At 1 year post‐PCI and clinical CYP2C19 genotyping at UF Health, 64.9% (137/211) of patients were prescribed a CPIC level A drug and 71.6% (151/211) were prescribed a CPIC A or B drug, in addition to their oral antiplatelet therapy. Results remained unchanged when we excluded patients aged ≥ 65 years to emulate the MarketScan population. The incidence of potential genotype‐guided prescribing opportunities (percentage of patients with actionable phenotypes who were prescribed the relevant pharmacogenetic drug) was 32% (**Table** [4](#cts12729-tbl-0004){ref-type="table"}).

Discussion {#cts12729-sec-0014}
==========

This study evaluated the use of pharmacogenetic drugs and the prevalence of corresponding actionable phenotypes among patients with incident PCI who were prescribed antiplatelet therapy. In this analysis, a national sample of privately insured patients within MarketScan was used to identify opportunities for pharmacogenetic testing. Different follow‐up times (1 through 5 years) after PCI were evaluated to mimic minimal and maximum retention times of patients in insurance plans and facilitate decision making regarding the short‐term and long‐term utility of multipharmacogene panel testing.

The analysis of genetic data at UF focused on five genes, which are commonly included on pharmacogenetic panels. The majority of patients analyzed had one or more actionable phenotypes considering these five genes, most commonly for *CYP2C19* and *CYP2C9.* Although the term "actionable genotype/phenotype" was used to refer to a phenotype that would trigger a change in a prescribing decision, it is important to point out that the knowledge of a "normal" phenotype may be equally valuable. For example, following the acute post‐PCI period, knowing that a patient prescribed ticagrelor or prasugrel has a normal *CYP2C19* genotype (e.g., *\*1/\*1*) could inform switching to clopidogrel in the event this patient is at high risk for bleeding or cannot afford or tolerate the potent antiplatelet agents.[25](#cts12729-bib-0025){ref-type="ref"} Therefore, a pharmacogene panel‐based testing can be clinically and economically valuable even if a "normal" genotype that would not trigger a change in therapy is encountered.

In the Pharmacogenomic Resource for Enhanced Decisions in Care and Treatment (PREDICT) cohort, 91% of patients who underwent preemptive genotyping (*n* = 9,589) were reported to have ≥ 1 actionable genotype.[6](#cts12729-bib-0006){ref-type="ref"} The PREDICT cohort included patients who underwent cardiac catheterization, presented with acute lymphocytic leukemia, or had at least a 40% likelihood of exposure to statin, clopidogrel, or warfarin over 3 years according to a prediction model.[6](#cts12729-bib-0006){ref-type="ref"} Patients were genotyped for *CYP2C19*, *CYP2C9*, and *VKORC1* in addition to *CYP3A5* and *TPMT*, which are relevant for tacrolimus and thiopurines, respectively. The latter two genes were not typed in our study, which may contribute to the lower prevalence of actionable phenotypes in our study compared with the PREDICT data. Another study reported that 99% of patients who were enrolled as part of the Mayo Clinic Right Drug, Right Dose, Right Time--Using Genomic Data to Individualize Treatment (RIGHT) protocol had actionable variants in the same genes evaluated in our study.[26](#cts12729-bib-0026){ref-type="ref"}, [27](#cts12729-bib-0027){ref-type="ref"} The lower prevalence of actionable genotypes in our study compared with the RIGHT cohort may be partially attributed to a high prevalence of CYP2D6 UM phenotype (8%) within the RIGHT cohort, which we did not assess for.[26](#cts12729-bib-0026){ref-type="ref"} This likely led to underestimation of the number of *CYP2D6‐*related actionable phenotypes in our study. Additionally, *SLCO1B1* carrier genotypes were more prevalent (\> 30%) among the RIGHT cohort, compared with our cohort (15%), which may be attributed to the lower prevalence of African Americans in the RIGHT cohort (\< 20%) compared with our UF population (48%).

Within MarketScan, we found that between 50% (1‐year follow‐up) and 68% (5‐year follow‐up) of post‐PCI patients were exposed to at least one pharmacogenetic drug in addition to oral antiplatelet therapy. Opioids, PPIs, simvastatin, ondansetron, selective serotonin re‐uptake inhibitors, and warfarin were among the frequently utilized CPIC medications in this cohort of patients. As a unique component of this study, we combined drug prevalence for patients within MarketScan and actionable phenotype prevalence data for patients with PCI at UF to project on national estimates of incident genotype‐guided prescribing opportunities, if genotyping using a multipharmacogene panel was performed at the time of PCI. We were particularly interested in estimating the short‐term and long‐term utility of panel testing that may translate into economic benefits for insurance plans. Therefore, we calculated a 1 year and 5 year incidence of genotype‐guided prescribing opportunities post‐PCI. Our results found a 1 year incidence of 39% for unique genotype‐guided prescribing beyond *CYP2C19*‐guided antiplatelet therapy. This value increased to 52% when the projection was performed using drug prevalence data over 5 years of follow‐up. Our findings on pharmacogenetic drug use are in line with a recently published study of eight million veterans, in which 55% of patients were documented to receive at least one CPIC level A in the period of 2011--2017.[28](#cts12729-bib-0028){ref-type="ref"} Using 1000 Genomes Project population estimates for actionable genotypes, the investigators projected that *SLCO1B1*‐simvastatin, *CYP2D6‐*tramadol, and warfarin*‐CYP2C9/VKORC1* would be the most prevalent genotype‐drug interactions in US veterans.[28](#cts12729-bib-0028){ref-type="ref"}

At UF, the incident genotype‐guided prescribing opportunities were determined at 32%. Although this was a slightly lower value than the projected estimate in MarketScan (39%), our results consistently suggest that preemptive genotyping could have led to genotype‐guided decisions in over a third of patients within the first year of PCI. There were some differences in utilization of pharmacogenetic drugs between the UF and MarketScan cohorts, such as different preferences for opioids and PPIs. This may be explained by institution‐specific prescribing practices, formulary differences, and the small sample size in the UF cohort. Because the prescription data in UF were collected for more recent years (2012--2018) than in MarketScan (2008--2015), secular trends such as shifts toward more potent statins (atorvastatin) in reaction to the 2013 updated practice guidelines[29](#cts12729-bib-0029){ref-type="ref"} were noted. Although the analysis in MarketScan captured only outpatient pharmacy dispensing data, UF prescription data were extracted from both inpatient and outpatient records, which may explain the higher and lower prevalence of some drugs, such as ondansetron and codeine (codeine was removed from the UF formulary in 2012), compared with MarketScan.

To our knowledge, our study is the first to focus specifically on patients with PCI, one of the most common settings for pharmacogenetic testing with high insurance reimbursement rates.[8](#cts12729-bib-0008){ref-type="ref"} Evaluating the prevalence of pharmacogenetic drugs and opportunities for genotype‐guided prescribing among patients with PCI is important as it marks a decision point and allows for quantification of cost and benefit of multigene panel testing. Such data may support a hybrid testing model (reactive/preemptive) whereby *CYP2C19* testing is ordered at the time of PCI (reactive testing) and done as part of a panel of multiple pharmacogenes (preemptive testing). Assuming the cost of panel‐based testing is similar to that of *CYP2C19* testing, this hybrid model would create minimal excess financial burden on the health system, while potentially improving prescribing decisions and treatment outcomes for multiple medications that a patient is prescribed across one\'s lifetime. Although the ultimate goal of precision medicine is to achieve wide implementation of preemptive genotyping, this may seem impractical at present, especially from the payers\' perspectives. A model, which focuses and preemptively genotypes high‐risk cardiovascular populations at the time of PCI for the common CPIC gene‐drug pairs, may be a reasonable and cost‐effective alternative.[30](#cts12729-bib-0030){ref-type="ref"}, [31](#cts12729-bib-0031){ref-type="ref"}

Strengths of this study include the use of two data sets (MarketScan and UF) to determine prescribing of pharmacogenetic drugs and identify the potential value of panel‐based testing. Although both genotype and prescription data were available at UF, the data represent local prescribing practices and are limited by the small sample size. On the other hand, MarketScan provides a national sample of healthcare encounter data for \> 25 million privately insured patients annually, thus allowing national extrapolations. In our analysis, we relied on the assumption of similarity between the two patient populations. Our results found a high prevalence of pharmacogenetic drug prescribing in both data sets, albeit with some differences within drug classes. Noteworthy, the actual incidence of potential genotype‐guided prescribing opportunities among UF patients (had genetic information been available) and the projected incidence within MarketScan was similar, thus validating our projections.

We acknowledge some limitations in our study. First, we did not capture medications paid out of pocket, and, therefore, medication prevalence in MarketScan might be underestimated. Second, MarketScan includes de‐identified data sets, which precluded linking UF genotype data to medication exposure data to formally assess generalizability. Third, data on race/ethnicity, which affect the prevalence of actionable genotypes, are not available within MarketScan. Our analysis in MarketScan extended from 2008 to 2015, which may not reflect recent changes in prescribing patterns; for example, the recent uptake of new oral anticoagulants or more potent statins. Fourth, we did not assess copy number variations in *CYP2D6* or *CYP2D6* deletion (*\*5*), which may have underestimated the prevalence of actionable *CYP2D6* phenotypes (IM, PM, and UM), and the projected incidence of genotype‐guided decisions for drugs affected by these phenotypes.

In summary, we found a high prevalence of pharmacogenetic medications among a national cohort of privately insured patients and our local UF Health PCI cohort. Further, we found a high prevalence of actionable phenotypes in the UF Health cohort. Combining two data sources, we estimated a 1‐year incidence of genotype‐guided prescribing opportunities at 39% among MarketScan beneficiaries with PCI, which was similar to an actual estimate of 32% within UF. Collectively, these data support the value of panel‐based testing.
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